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Abstract
Purpose: Carcinosarcoma of the breast is a rare yet highly aggressive tumor ac-
counting for <1% of all breast cancers, for which guidance on optimal management 
and prognosis are sparse. The purpose of this study was to investigate population‐
based treatment patterns and overall survival (OS) outcomes in patients with this 
diagnosis.
Materials and Methods: We queried the National Cancer Database for patients di-
agnosed with carcinosarcoma of the breast. All patients included were treated with 
surgery in the form of mastectomy or lumpectomy, with or without chemotherapy 
and/or radiation therapy. Patients with metastatic disease were excluded. Kaplan‐
Meier analysis was used to estimate OS. Univariate and multivariable Cox analyses 
were used to determine predictive factors of OS.
Results: A total of 329 patients from 2004 to 2012 were identified. Median age at 
diagnosis was 58 years (range, 24‐90). Patients had T1 (21%), T2 (44%), T3 (25%), 
or T4 disease (10%). Most patients were node‐negative at diagnosis (77%). Breast 
conservation surgery was utilized in 33% of patients. Chemotherapy was used in 66% 
of patients. Less than half (44%) of patients received radiation therapy to a median 
dose of 50.4 Gy (range 35‐56 Gy), with a median 10 Gy boost used in 76%. With a 
median follow‐up of 40.0 months, 3‐ and 5‐year OS for all patients was 74% and 
60%, respectively. Kaplan‐Meier estimates revealed the 3‐yr OS was 80% in patients 
receiving chemotherapy vs 59% without chemotherapy (P < 0.001). The 3‐yr OS 
was 82% in patients receiving RT vs 66% without RT (P = 0.001). On multivariable 
analysis, OS was significantly influenced by Charlson‐Deyo comorbidity index, in-
surance status, clinical T stage, surgical margin status, and treatment group, with 
trimodality therapy (HR: 0.45, 95% CI: 0.27‐0.78; P = 0.004) and surgery plus CT 
(HR: 0.54, 95% CI: 0.33‐0.90; P = 0.02) being associated with the greatest OS. 
Logistic regression revealed only younger patients were more likely to receive trimo-
dality therapy.
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1 |  INTRODUCTION
Carcinosarcoma of the breast is a rare and highly aggressive 
tumor which accounts for <1% of all new cases of breast 
cancer annually.1 Histologically, carcinosarcomas are poorly 
differentiated cancers exhibiting carcinoma cells intermixed 
with a malignant nonepithelial mesenchymal component 
that lacks a transition zone between these two malignant cell 
types.2,3 The malignant mesenchymal component in these 
tumors can include elements of chondroid, osseous, rhab-
domyoid and even neuroglial differentiation. Also known 
as metaplastic breast cancer with mesenchymal differenti-
ation, it is one of the five distinct subtypes of metaplastic 
breast cancer (MBC) characterized by the 2011 World Health 
Organization Working Group.4 Other subtypes of MBC in-
clude squamous cell carcinoma, low‐grade adenosquamous 
carcinoma, spindle cell carcinoma, and fibromatosis‐like 
metaplastic carcinoma. These cancers are typically hormone 
receptor negative, but hormone receptor status does not ap-
pear to affect prognosis in these patients.5
Compared to invasive ductal (IDC) and invasive lobu-
lar (ILC) breast cancers, carcinosarcoma is more likely to 
present with a larger primary tumor and less likely to have 
lymphatic involvement at diagnosis.6 Carcinosarcoma has an 
increased tendency for hematogenous dissemination, with 
lung and pleural metastases being the most common site of 
distant disease.7 Accordingly, MBC typically presents with a 
more advanced stage at diagnosis and both local and distant 
failure rates are higher relative to IDC or ILC.8 Local recur-
rence rates are particularly high, with one study reporting 
53% at 2 years compared to an expected 10% or less in other 
invasive cancers, warranting the need for aggressive local 
therapy.9 This more aggressive clinical course for MBC as 
a whole appears to hold true when compared specifically to 
triple‐negative breast cancer (TNBC).10
As carcinosarcoma is an infrequent entity lacking ran-
domized trials, there is little guidance on the optimal 
treatment of these tumors. Furthermore, many studies ex-
amining carcinosarcoma also include patients with several 
other MBC subtypes and a heterogeneous array of clinical 
factors, making accurate prognostication and risk stratifi-
cation difficult to ascertain. Studies specific to carcinosar-
coma treatment and outcomes are limited to only a handful 
of cases, underscoring the need for further investigation to 
better understand the clinical course and ideal management 
of these patients.
Our aim was to evaluate patient characteristics and treat-
ment approaches as they relate to survival outcomes in a 
modern cohort of patients diagnosed with carcinosarcoma 
of the breast using a large hospital‐based cancer registry, the 
National Cancer Database (NCDB). We hypothesized that 
survival would be improved in patients treated with multi-
modal therapy with chemotherapy (CT), radiation therapy 
(RT), or both compared to surgical resection alone.
2 |  MATERIALS AND METHODS
2.1 | Data source and study population
We reviewed the NCDB Participant User File (PUF) of 
breast tumors to identify all patients diagnosed with carcino-
sarcoma of the breast (histology 8980). NCDB is a joint pro-
gram of the American College of Surgeons and the American 
Cancer Society. Data are available on patients diagnosed at 
Commission on Cancer (CoC) accredited cancer centers, cap-
turing approximately 70% of all newly diagnosed malignan-
cies in the United States annually.11 Data on patient, tumor, 
and treatment characteristics are collected and submitted to 
the NCDB from CoC‐accredited oncology registries using 
standardized coding and data item definitions. The Health 
Insurance Portability and Accountability (HIPAA)‐compli-
ant NCDB PUF contains only de‐identified patient and center 
information and did not require institutional review board 
approval.
De‐identified data for patients diagnosed with carcinosar-
coma of the breast (International Classification of Disease 
for Oncology, 3rd edition [ICD‐O‐3] code 8980) who were 
aged 18‐90 and diagnosed between 2004 and 2012 were eval-
uated. Other non‐IDC/ILC histologies including metaplas-
tic carcinoma NOS, squamous cell carcinoma, and spindle 
cell carcinoma were excluded. In our analysis, we excluded 
patients with distant metastatic disease at time of diagnosis 
and incomplete treatment data. Demographic and clinical 
data included age, gender, race, year of diagnosis, stage, 
grade, Charlson‐Deyo comorbidity index (CDCI), treatment 
location and facility type, primary insurance status, type of 
treatment (surgery, RT, or CT). Surgery included either mas-
tectomy or partial mastectomy. The groups that were included 
Conclusions: Carcinosarcoma of the breast is associated with relatively poor rates of 
OS. The addition of CT and RT to surgery improves OS. Trimodality therapy and 
surgery plus CT were associated with the greatest OS compared to surgery alone.
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in our analysis were surgery alone, surgery plus CT, surgery 
plus RT, and trimodality therapy consisting of surgery plus 
chemoradiotherapy (CRT).
2.2 | Statistical analysis
Overall survival was calculated from diagnosis until death 
or last follow‐up. The Kaplan‐Meier method was used to es-
timate OS probabilities and Cox analyses were performed. 
Patients with incomplete data regarding surgery, chemother-
apy, or radiotherapy were excluded from survival analysis. In 
addition to these analyses, age, year of diagnosis, race, insur-
ance status (private vs uninsured vs government insurance), 
CDCI, T and N stage, facility type (academic vs non‐aca-
demic), margin status, surgery type, and treatment strategy 
were used on univariate analysis. Variables at P < 0.05 on 
univariate testing were entered into multivariable analy-
ses using the Cox proportional hazards model. To confirm 
appropriate selection of predictive variables entered into 
multivariable analysis, backwards stepwise regression was 
utilized. Significance was considered at P < 0.05, and all 
significance levels were 2‐sided. Binary logistic regression 
was performed to obtain odds ratios for factors predictive of 
receiving trimodality therapy, with factors with P < 0.10 on 
univariate analysis entered into the model for stepwise selec-
tion. IBM® SPSS® Statistics, version 23 was applied for all 
statistical analyses.
3 |  RESULTS
3.1 | Demographics, patient, tumor, and 
treatment characteristics
We identified a total of 329 patients treated between 
2004 and 2012. Median follow‐up was 40 months (range 
0‐123.8 months). Patient characteristics and treatment 
strategies are summarized in Table 1. The majority of dis-
ease was hormone receptor negative and human epidermal 
growth factor receptor (HER)2/neu (c‐erbB2) non‐amplified. 
Surgery was mastectomy in 65.4% and partial mastectomy 
in 31.6% of patients. Radiation therapy was administered to 
43.2% of all patients. Of patients receiving breast conserva-
tion surgery, adjuvant radiation therapy was utilized in 71% 
of patients receiving partial mastectomy. Of patients receiv-
ing mastectomy, postmastectomy RT (PMRT) was utilized 
in 32% of patients. Patients receiving PMRT had pathologic 
T3 or 4 disease in 63%, pathologic node positivity in 35%, 
positive margins in 9%, with no patients having at least 1 of 
the above factors. The median RT dose was 50.4 Gy (range, 
35.0‐55.8 Gy). A boost was used in 28.9% of patients, with 
a median dose of 10.0 Gy (1.6‐18.4 Gy). Chemotherapy was 
also used as part of initial treatment in 66.0% of patients, of 
which 18% received neoadjuvant systemic therapy starting 
at least 30 days prior to definitive surgery and the remaining 
82% received adjuvant chemotherapy. Distribution of treat-
ment groups were surgery alone (77 patients, 23.4%), surgery 
plus CT (96 patients, 29.2%), surgery plus RT (26 patients, 
7.9%), and trimodality therapy (116 patients, 35.3%). There 
were 14 patients (4.3%) with incomplete details regarding ei-
ther surgery, RT or CT.
3.2 | Outcomes
The median OS for the entire cohort was 8.7 years. At the 
time of analysis, 117 patients had died. Estimated 3‐year 
and 5‐year OS was 74% and 60%, respectively, for all pa-
tients. Median OS in patients with clinical T2, T3, and T4 
disease was 8.7 (95% CI: 6.8‐10.7), 3.5 (95% CI: 2.6‐4.4), 
and 3.6 years (95% CI: 1.1‐6.0), respectively (P < 0.001) 
(Figure 1A). There was no statistical difference in OS be-
tween patients with clinically node‐negative and node‐posi-
tive disease at diagnosis (P = 0.166). For patients diagnosed 
in 2004‐2008 vs 2009‐2012, there was no significant differ-
ent in OS (P = 0.682). Median OS in patients with CDCI of 
1 and 2 was 3.3 (95% CI: 2.2‐4.5) and 3.0 years (95% CI: 
1.0‐5.1), respectively, while median OS was not reached 
in patients with CDCI of 0 (P < 0.001) (Figure 1B). When 
stratified by treatment group, estimated 3‐ and 5‐year OS was 
85% and 72%, respectively, for patients treated with trimo-
dality therapy, 74% and 68% for patients receiving surgery 
and CT (but not RT), 67% and 59% for patients receiving 
surgery and RT (but not CT), and 54% and 30% for patients 
receiving surgery alone (P < 0.001) (Figure 2A). Kaplan‐
Meier OS curves of patients stratified by surgical margin 
status are shown in Figure 2B, with 3‐ and 5‐year OS 76% 
and 63% for negative margins, and 53% and 35% for posi-
tive margins, respectively (P < 0.001). When stratified by 
treatment with chemotherapy, the 3‐ and 5‐year OS was 80% 
and 70% in patients receiving chemotherapy vs 59% and 41% 
without chemotherapy (P < 0.001) (Figure 2C). The 3‐ and 
5‐year OS was 82% and 72% in patients receiving RT vs 66% 
and 50% without RT (P = 0.001) (Figure 2D).
3.3 | Univariate and multivariable analyses
On univariate and multivariable analysis, CDCI, T stage, 
margin status, and treatment modality were all associated 
with overall survival (Table 2). Patients with CDCI of 1 (HR: 
2.18, 95% CI: 1.30‐3.68; P = 0.003), positive surgical mar-
gins (HR: 3.37, 95% CI: 1.83‐6.24; P < 0.001), and T stage 
T2 (HR: 2.79, 95% CI: 1.24‐6.27; P = 0.01), T3 (HR: 4.87, 
95% CI: 2.14‐11.09; P < 0.001), or T4 (HR: 6.70, 95% CI: 
2.62‐17.10; P < 0.001) all were associated with worse OS. 
Treatment with trimodality therapy (surgery, CT, and RT) 
(HR: 0.45, 95% CI: 0.27‐0.78; P = 0.004) or surgery plus 
chemotherapy (HR: 0.54, 95% CI: 0.33‐0.90; P = 0.02) was 
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associated with improved OS. In the small subset of patients 
(n = 26 patients, 7.9%) treated with only surgery and RT, 
there was no significant difference in OS compared to surgery 
alone (P = 0.26). Nodal status and surgery type (mastectomy 
vs partial mastectomy) did not significantly influence OS in 
our analyses. Multivariable logistic regression revealed only 
younger patients had higher likelihood of receiving trimodal-
ity therapy, while CDCI, race, year of diagnosis, facility type, 
insurance status, T or N stage, or margin status did not (Table 
3).
4 |  DISCUSSION
Carcinosarcoma is an aggressive subtype of breast cancer 
for which data on prognosis and ideal management is sparse. 
T A B L E  1  Patient‐ and treatment‐related characteristics (n = 329)
Characteristic Value
Age, median (range) 58 y (range, 24‐90)
Race
White 262 (79.6%)




























































Not recorded 212 (64.5%)
Treatment group
Surgery alone 77 (23.4%)
Surgery + CT 96 (29.2%)
Surgery + RT 26 (7.9%)
Surgery + CT + RT 116 (35.3%)
Either RT or CT details unknown 14 (4.3%)




Either no RT or unknown 204 (62.0%)
Boost Dose, median (range) 10.0 Gy (1.6‐18.4 Gy)
T A B L E  1  (Continued)
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In this study, we used the NCDB to evaluate contemporary 
treatment approaches and their impact on survival in patients 
diagnosed with carcinosarcoma of the breast. Our study 
found that treatment with trimodality therapy or surgery and 
chemotherapy was associated with a significant improve-
ment in overall survival. In addition, we identified other pa-
tient and treatment‐related factors associated with improved 
survival in this cohort.
Highlighting the underlying heterogeneity of various 
subtypes of metaplastic breast cancer, the most recent WHO 
guidelines have emphasized the relevance of a descriptive 
sub‐classification of these tumors given that carcinosarcoma, 
also known as metaplastic carcinoma with mesenchymal 
differentiation, differs not only histologically, but clinically 
from other metaplastic tumors.4 Due to the rarity of this 
diagnosis, evaluating practice patterns and outcomes on a 
national level are crucial to outlining optimal management. 
Here, we present a large study reporting patterns of care and 
survival outcomes of carcinosarcoma of the breast. Recent 
studies have shown that metaplastic breast cancer (MBC) is 
more aggressive than triple‐negative breast cancer (TNBC), 
an entity with which it has often been conflated. Compared 
to TNBC, patients diagnosed with MBC more likely present 
with advanced stage, have twice the rate of local recurrence, 
and more often die of their disease.10 Population‐based stud-
ies of MBC as a whole have shown worse overall survival 
than non‐MBC patients irrespective of hormone receptor 
status, implying MBC does independently confer a survival 
detriment as previously thought.12 Despite worse outcomes 
compared to non‐MBC breast cancers, including TNBC, 
no guidelines exist regarding the optimal treatment of these 
patients.
Most patients in our study were treated with mastectomy, 
perhaps due to the fact that only 20.6% of patients presented 
with T1 disease in our series and the majority of patients 
presented with large primaries. Mastectomy has been shown 
to be used more frequently in MBC compared to non‐MBC 
due to larger size at presentation, and rates are similar when 
adjusted for T stage.13 Despite this, patients who underwent 
breast‐conserving surgery did not experience inferior OS 
compared to mastectomy, consistent with well‐established 
randomized data.14 However, positive surgical margins were 
associated with worse outcomes in our series, consistent with 
the non‐MBC literature.15 While adjuvant therapy may re-
duce recurrence risks in the setting of a positive margin, it has 
not been shown to completely mitigate the worse outcomes 
seen in these patients.16 Unfortunately, the rates of re‐resec-
tion are not documented in the NCDB, and margins are only 
documented as negative vs positive, so the impact of close or 
focally positive margins on outcomes cannot be determined 
from the current analysis. Furthermore, only 22.5% of pa-
tients had clinically node‐positive disease at diagnosis, which 
is consistent with previous observations that carcinosarcoma 
has a propensity for local and hematogenous spread, rather 
than lymphatic spread.17 These patterns of failure inherent to 
carcinosarcoma may additionally explain why nodal involve-
ment at diagnosis did not affect OS in our study. Given that 
disease‐specific mortality is primarily driven by high rates of 
F I G U R E  1  Overall survival. A, by tumor stage (T2 vs T3 and T4 P < 0.001). B, by CDCI (between all groups P < 0.001)
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distant metastases inherent to the natural history of carcino-
sarcoma, irrespective of nodal status, may at least partially 
explain why clinical node‐positivity did not impact survival 
in our series.
Metaplastic breast cancer is thought to be resistant to 
conventional chemotherapy with rates of progression as high 
as 83% in patients treated with neoadjuvant chemotherapy, 
and modest partial response to taxane‐based regimens and 
no responders to anthracycline and cyclophosphamide‐based 
regimens.18 Although details regarding specific chemother-
apeutic agents and their doses are unavailable in our cohort, 
we did observe a substantial survival benefit to the use of 
chemotherapy in the current study, with 5‐year OS 70% in 
patients receiving systemic therapy compared to 41% in 
F I G U R E  2  Overall survival. A, by treatment group (P < 0.001). B, by surgical margin status (P = 0.003). C, by use of RT (P = 0.001) and 
D, use of CT (P < 0.001)
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patients not treated with systemic therapy. A small subset 
of patients had hormone receptor‐positive disease in our se-
ries, and <5% of patients received adjuvant hormonal ther-
apy, although receptor status has previously been shown to 
not affect prognosis in MBC.19 Data on the role of endo-
crine therapy are currently sparse, limited to isolated case 
reports.20 Of increasing interest in carcinosarcoma and MBC 
as a whole is the use of targeted therapies, particularly the 
epidermal growth factor receptor (EGFR) pathway, given 
that 70%‐80% of MBC overexpresses EGFR but not human 
epidermal growth factor receptor (HER)2/neu (c‐erbB2), for 
which no data currently exist on the effectiveness of targeted 
Univariate Multivariable
HR (95% CI) P value HR (95% CI) P value
Age 1.02 (1.01‐1.04) <0.001 1.00 (0.98‐1.02) 0.92
Race
White Reference
Nonwhite 1.10 (0.70‐1.72) 0.67 0.62 (0.35‐1.09) 0.10
Year of diagnosis 1.02 (0.94‐1.10) 0.63 1.01 (0.92‐1.11) 0.88
CDCI
0 Reference
1 2.83 (1.83‐4.38) <0.001 2.18 (1.30‐3.68) 0.003
2 3.39 (1.56‐7.38) 0.002 2.41 (0.94‐6.20) 0.07
Facility program type
Academic Reference
Non‐academic 1.03 (0.67‐1.59) 0.91 0.81 (0.49‐1.32) 0.39
Insurance status
Private Reference
Government 2.13 (1.44‐3.16) <0.001 2.07 (1.39‐3.32) 0.002
Uninsured 1.66 (0.70‐3.92) 0.25 3.00 (1.20‐7.48) 0.019
Clinical T stage
T1 Reference
T2 2.03 (1.08‐3.83) 0.03 2.79 (1.24‐6.27) 0.01
T3 4.20 (2.21‐7.99) <0.001 4.87 (2.14‐11.09) <0.001
T4 4.22 (2.00‐8.94) <0.001 6.70 (2.62‐17.10) <0.001
Clinical N stage
N0 Reference
N1 1.12 (0.70‐1.80) 0.63 1.04 (0.58‐1.88) 0.90
N2 2.72 (1.32‐5.63) 0.007 1.05 (0.44‐2.54) 0.91





0.78 (0.52‐1.17) 0.23 1.05 (0.62‐1.78) 0.86
Margin status
Negative Reference
Positive 2.21 (1.28‐3.82) 0.004 3.37 (1.83‐6.24) <0.001
Treatment modality
Surgery alone Reference
Surgery +CT 0.42 (0.27‐0.67) <0.001 0.54 (0.33‐0.90) 0.02
Surgery +RT 0.53 (0.26‐1.05) 0.07 0.66 (0.33‐1.35) 0.26
Surgery +CT + 
RT
0.30 (0.19‐0.49) <0.001 0.45 (0.27‐0.78) 0.004
T A B L E  2  Univariate and 
multivariable Cox proportional hazards 
model for overall survival
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agents.21 Other identified pathways harboring potential tar-
gets in carcinosarcoma include the phosphoinositide 3‐kinase 
(PI3K)/AKT, MAP kinase signaling, and epithelial‐mesen-
chymal transition pathways.22
Interestingly, post‐lumpectomy radiation therapy was uti-
lized in 71% of patients receiving lumpectomy, considerably 
lower than approximately 87% in non‐metaplastic, non‐car-
cinosarcoma breast cancer observed in other NCDB‐based 
analyses of breast cancer.12 Previously, population‐based 
studies have shown an independent improvement in both OS 
and disease‐specific survival advantage for patients receiv-
ing RT for patients with MBC when using the Surveillance, 
Epidemiology, and End Results (SEER) database.23 Adjuvant 
RT has been consistently shown to reduce breast cancer mor-
tality both as a part of breast conservation therapy and in se-
lect postmastectomy patients.24,25 The reasons for omitting 
RT as part of BCT in 29% of eligible patients, such as patient 
refusal or physician discretion, are unavailable in the NCDB 
and we are therefore unable to analyze these data in the cur-
rent study.
Postmastectomy radiotherapy was utilized in 32% of 
carcinosarcoma patients treated with mastectomy, similar 
to approximately 30% of non‐carcinosarcoma mastectomy 
patients.26 All of the patients in our current series receiving 
PMRT had either pT3‐4, node‐positivity, or positive mar-
gins. Further conclusions in this cohort are difficult to draw 
from the current series, however, as the number of patho-
logic nodes nor RT nodal volume data was not consistently 
reported in the NCDB. No data exist currently to a role of 
PMRT in carcinosarcoma other than classic indications, and 
further investigation is warranted.
In our study, Kaplan‐Meier estimates did confirm treat-
ment with RT was associated with a significant improvement 
in both 3‐ and 5‐year survival. On multivariable analysis, 
however, the small subset of patients who were treated with 
surgery and RT but not CT did not experience improved OS 
compared to surgery alone. This is unsurprising given that 
only 7.9% of patients were treated with surgery and RT, by far 
representing the smallest treatment group in our current series.
We found that patients treated with either trimodality 
therapy or surgery and chemotherapy experienced the great-
est overall survival in this cohort. To determine factors as-
sociated with receipt of trimodality therapy, we performed 
logistic regression, with only younger age being significantly 
predictive. Notably, CDCI, T and N stage, as well as margin 
status did not predict for treatment with trimodality therapy. 
Nevertheless, trimodality therapy remained independently 
associated with improved overall survival on multivariable 
analysis. While the literature characterizing outcomes in met-
aplastic breast cancer as a whole is scarce, the characteristics 
and outcomes in carcinosarcoma are even less reported on. 
Data are often limited individual case reports or small case 
series with conflicting results about prognosis and response 
to treatment.1,27,28 In this series of carcinosarcoma of the 
breast, we demonstrate the previously unreported benefit of 
trimodality therapy in this patient population.
Although the strengths of our retrospective study include 
the large number of patients, there are considerable limita-
tions. Our study is affected by limitations inherent to ret-
rospective reviews and the nature of the NCDB as our data 
source. Carcinosarcoma histology is reported by individual 
institutions to the NCDB, but there is no central pathology 
review. Whether these patients had tumors with purely car-
cinosarcoma or had a partial component of carcinosarcoma 
is not reported, which may influence natural history and out-
comes. There is potential selection bias as well, which may in 
part explain why patients treated with multimodal therapies 
experience improved OS. Patient selection may also explain 
why median survival of generally healthier patients, those 
T A B L E  3  Multivariable logistic regression for factors predictive 
of trimodality therapy
Characteristic OR (95% CI) P value
Age 0.95 (0.93‐0.97) <0.001
Race
White Reference
Nonwhite 1.01 (0.49‐2.08) 0.98
Year of diagnosis 1.09 (0.98‐1.21) 0.10
CDCI
0 Reference
1 0.94 (0.22‐4.04) 0.93
2 0.51 (0.10‐2.59) 0.42
Facility program type
Academic Reference
Non‐academic 1.10 (0.58‐2.07) 0.78
Insurance status
Private Reference
Government 1.88 (0.55‐6.50) 0.31
Uninsured 1.17 (0.31‐4.42) 0.82
Clinical T stage
T1 Reference
T2 1.49 (0.48‐4.64) 0.50
T3 1.19 (0.42‐3.36) 0.75
T4 1.99 (0.68‐5.85) 0.21
Clinical N stage
N0 Reference
N1 0.48 (0.14‐1.67) 0.25
N2/N3 0.64 (0.16‐2.52) 0.52
Margin status
Negative Reference
Positive 3.62 (0.98‐13.33) 0.053
CDCI, Charlson/Deyo Comorbidity Index.
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with CDCI of 0, did not meet median overall survival, al-
though CDCI did not predict for trimodality therapy. Further 
details of treatment, such as type and frequency of systemic 
therapy, radiotherapy modality, surgical management of the 
axilla, a standardized definition of positive margins, and use 
of salvage therapies are unavailable in the NCDB. Details on 
regional nodal irradiation volumes were inconsistently re-
corded and therefore excluded from our analysis. The NCDB 
records overall survival, but additional important endpoints 
including toxicity and quality of life data, local and regional 
control, as well as disease‐specific survival are omitted from 
the NCDB and therefore, we are unable to draw any con-
clusions with respect to these topics. Regardless, our work 
represents the largest series of this rare, aggressive disease 
to‐date and provides a basis for further prospective studies.
5 |  CONCLUSIONS
Carcinosarcoma of the breast is a rare, distinct entity of 
breast cancer characterized by highly aggressive behav-
ior with a propensity for local and distant relapse despite 
low rates of lymphatic spread. Given a scarcity of stud-
ies investigating natural history and treatment outcomes in 
these patients, guidance on optimal management of these 
patients is severely lacking. Based on our findings, mul-
timodal therapy provides a marked survival advantage, 
with patients treated with trimodality therapy consisting of 
surgery, chemotherapy, and radiotherapy experiencing the 
most favorable survival.
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